NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
Priority Review
LAMIVUDINE; STAVUDINE (lamivudine; stavudine) by Matrix Surgical USA is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 8h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMIVUDINE; STAVUDINE is a fixed-dose combination oral tablet containing two nucleoside reverse transcriptase inhibitors (NRTIs) for treating HIV-1 infection in adults and children weighing at least 6 kg. The combination works by inhibiting HIV reverse transcriptase to reduce viral replication. This is a pre-launch NDA product currently under development by Matrix Surgical USA.
PRE_LAUNCH
Pre-launch stage indicates limited current commercial activity; career growth will depend on regulatory approval success and market penetration post-launch.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE; STAVUDINE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.